wortmannin and Prostatic-Neoplasms--Castration-Resistant

Aldo-keto reductase (AKR) 1C3 catalyzes the synthesis of active androgens that promote the progression of prostate cancer. AKR1C3 also contributes to androgen-independent cell proliferation and survival through the metabolism of prostaglandins and reactive aldehydes. Because of its elevation in castration-resistant prostate cancer (CRPC) tissues, AKR1C3 is a promising therapeutic target for CRPC. In this study, we found a novel potent AKR1C3 inhibitor,

Topics: Aldo-Keto Reductase Family 1 Member C3; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mice, Inbred BALB C; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays